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, Kureha, Tokyo, Japan) is an
oral carbonaceous adsorbent used in pre-dialysis
renal failure patients to adsorb uremic toxin such as
indoxyl sulfate, indoxyl-D-glucuronide and p-cresol.
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When tryptophan is introduced to the body, it is me-
tabolized into indole in gastrointestinal tract by bac-
teria. Indole is then absorbed into the body and
change into a potent uremic toxin, indoxyl sulfate in
liver
1)
. Serum indoxyl sulfate level is correlated with
CKD progression. In uremic rat model, administration
of indoxyl sulfate decreases renal function and induces
glomerular sclerosis by stimulating transforming growth
factor- 1 (TGF- 1), tissue inhibitor of metalloproß ß -
teinase-1, and pro- 1 collagenα 2).
There have been many overseas studies showing
the effect of AST-120 in delaying progression to
end-stage renal disease (ESRD), hence prolonging
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Purpose: AST-120 is known to delay progression of chronic kidney disease (CKD) when combined
with other proven therapy. AST-120 is an oral adsorbent for uremic toxin, such as indoxyl sulfate from
the gastrointestinal tract. There have been a lot of studies to show its effect in other countries, but
there are few studies done in Korea yet.
Methods: 195 patients were included in the study (mean age, 64±14 years; diabetes mellitus (DM),
104 patients; male, 130 patients). The patients with CKD who started AST-120 and maintained the
medication for at least 6 months were enrolled. The patients’ laboratory results for 6 months before
and after administrating AST-120 was surveyed. Then the rate of patients’ renal functional deterioration
was compared before and after AST-120. In addition, adverse effects during the medication were
surveyed.
Results: There were no statistically significant differences in laboratory data between before and after
AST-120 administration. But, after administrating AST-120, the renal deterioration slope has blunted
significantly from -0.0123±0.0318 to -0.0013±0.0184 dL/mg/month (p<0.01) in 1/sCr and from -1.1423±
2.3906 to 0.0639±1.3825 ml/min/1.73m2/month (p<0.01) in estimated glomerular filtration rate (eGFR).
There were no differences between DM and non-DM patients in the effect of AST-120, as well as
ages over 70 and below 70. There were no serious adverse effects during medication.
Conclusion: This study showed that AST-120 had additive effect on retarding the CKD progression
when combined with established therapy regardless of DM and ages without serious adverse effects.
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the interval to inception of dialysis
3-12)
. However,
there were few studies done in Korea.
In this study, the effect of AST-120 on delaying
the progression from CKD to ESRD was examined in





Clinical records of 310 patients with CKD who
started AST-120 between September 2005 and
September 2009 in outpatient department of Gangnam
Severance hospital were reviewed retrospectively.
The patients who met following inclusion criteria were
enrolled in the study: (1) CKD (serum creatinine:
1.5-6.0 mg/dL; eGFR: 15-60 mL/min/1.73m
2
) pati-
ents otherwise stable hemodynamically and metaboli-
cally; (2) no recent history of comorbidity as men-
tioned below at exclusion criteria. The patients who
met the following criteria were excluded: (1) patients
who failed to visit outpatients department or refuse to
blood sampling for 2 consecutive session (for 4
months); (2) malnutrition or a serum albumin 3.0≤
g/dL
13)
; (3) major cardiovascular event (acute myo-
cardial infarction, angina undergone coronary angio-
plasty); (4) hemoglobin A1c >8.1% in diabetics
14)
; (5)
acute kidney injury; (6) use of systemic immunosup-
pressive therapy; (7) cancer; (8) alcoholics or drug
abuse; (9) inflammatory bowel disease, chronic
diarrhea, malabsorption; (10) hepatic disease (hepa-
titis, cirrhosis, hepatic failure, viral carrier, OT/PT
elevation above normal range); (11) non-compliance.
Out of 310 patients screened, 195 patients met the
above criteria. The most common reasons for exclu-
sion were non-compliance (n=35; 30.7%), starting
renal replacement therapy (n=22; 19.3%).
The patients were encouraged to have low protein
diet (0.8-1.0 g protein/kg body weight/day) and salt
restriction (<7-8 g/day). Strict blood sugar control
was supplemented for those with DM. The patients
were taking angiotensin-converting enzyme inhibitor
(ACEi) or angiotensin II receptor blocker (ARB) if
not contraindicated. And the blood pressure was
strictly controlled to maintain below 130/80 mmHg in
patient without proteinuria or proteinuria under 1 g/
day, and 125/75 mmHg in patient with proteinuria
over 1 g/day.
2. Administration of AST-120
The patients received 2 g of AST-120 between
meals 3 times a day for at least 24 weeks. The pa-
tients who refused to take the medicine even a bit due
to various reasons were excluded. Since AST-120
is an adsorbent, simultaneous drug administration was
carefully avoided.
3. Clinical parameter
During the study periods, CBC with differential count,
blood urea nitrogen (BUN)/creatinine, total chole-
sterol, albumin, HbA1c, blood pressure, pulse rate,
body weight were measured every 2 months.
4. Evaluation of the effect of AST-120 on
deterioration of renal function
The gradient of renal functional deterioration was
evaluated as the slope of the reciprocal serum crea-
tinine level (1/sCr)
15)
, and by eGFR obtained from
modified MDRD (Modification of Diet in Renal Dis-
ease) equation
16)
before and after administration of
AST-120 preferably every 2 months. And, subgroup
analyses according to the presence of DM, age of 70
were conducted. In addition, adverse effects were
surveyed during medication.
5. Statistical analysis
The analyses were performed using SPSS for
window version 17.0 (SPSS Inc., Chicago, IL, USA)
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and data are expressed as the mean SD.±
Patient backgrounds were analyzed by the Student s’
t-test and the χ2-test for continuous and categorical
data, respectively. P-values less than 0.05 were
considered to be statistically significant.
RESULTS
1. Clinical and biochemical characteristics
Clinical and biochemical characteristics of 195
selected patients are shown in Table 1. The ages of
the group were 64 14 years, and 130 patients were±
male (66.7%), and 104 patients had DM (53.3%). The
eGFR of the patients at the point when AST-120 was
administered was 25.82 7.58 ml/min/1.73m± 2, compa-
tible to CKD stage 3 and 4 according to the GFR sta-
ging in the Kidney Disease Outcome Quality Initiative
(K/DOQI) guidelines proposed by the US National
Kidney Foundation
17)
. Mean Hemoglobin level was
11.7 1.6 mg/dL and hematocrit was 35.0 4.9%. Blood± ±
pressure was controlled with at least 1 anti-hyper-
tensive medication to target systolic pressure of 130
mmHg and diastolic pressure of 75 mmHg (beta bloc-
ker, 60 pts; ACEi 92 pts; ARB, 107 pts; calcium chan-
nel blocker, 76 pts). Mean HbA1c of DM patients
were 7.9%. Underlying renal diseases were shown in
Table 2. DM nephropathy was the most common etio-
logy of CKD (104 pts; 53.3%) and hypertensive ne-
phropathy was the second most common etiology (58
pts; 29.7%).
The mean values of biochemical parameter for 6
months before and after AST-120 administration were
calculated. There were no statistically significant dif-
ferences in biochemical parameters between before
and after taking AST-120 (Table 3). And there were
no statistically significant differences in clinical and
biochemical characteristics between DM group and
non-DM group or between ages over and below 70s
(Table not included).
2. Changes in reciprocal serum creatinine and
eGFR slope with AST-120













sCr at starting AST-120
(serum creatinine; mg/dL)

















Abbreviations: BUN, blood urea nitrogen; Cr, creatinine;
DBP, diastolic blood pressure; eGFR, estimated glom-
erular filtration rate; SBP, systolic blood pressure; T,
total.












Abbreviation: DM, diabetes mellitus.




































p<0.05, significantly different between before AST-
120 and after AST-120.
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The gradient of 1/sCr before and after administrating
AST-120 was -0.0123 0.0318 and -0.0013 0.0184± ±
dL/mg/month (p<0.01), respectively. The gradient of
eGFR before and after AST-120 was -1.1423±
2.3906 and 0.0639 1.3825 mL/min/1.73m± 2/month (p<
0.01), respectively (Fig. 1A, 1B). After the patients
started taking AST-120, the slope of 1/sCr and eGFR
has been alleviated. There were statistically significant
differences in estimated GFR and 1/sCr of pati ents
between before and after administrating AST-120.
3. The difference in effects of AST-120 in DM vs.
non-DM patients
The subgroups of DM and non-DM patients were
comprised of 104 patients and 91 patients, respec-
tively. In DM subgroup, the slope of 1/sCr has blunted
from -0.0186 0.0230 to -0.0017 0.0152 dL/mg/± ±
month (p<0.01), and that of eGFR has blunted from
-1.2793 2.1370 to -0.0628 1.2171 mL/min/1.73m± ± 2/
month (p<0.01). On the other hand, in non-DM group,
the slope of 1/sCr has been alleviated from -0.0132±
0.03118 to 0.0037 0.0193 dL/mg/month (p<0.01),±
and that of eGFR has blunted from -0.9940 2.6182±
to 0.2541 1.5472 mL/min/1.73m± 2/month (p<0.01).
Both subgroups showed statistically significant blun-
ting of the slope of 1/sCr and eGFR between before
and after AST-120 administration. There were no
statistically significant differences between DM vs.
non-DM subgroups in the effects of AST-120. (Fig.
2A, B)
Fig. 1. (A), (B) pre- vs. post-treatment slope on reci-
procal of serum creatinine (1/sCr) and estimated
GFR (eGFR) in total patients. The figures show
that the renal deterioration gradient has blunted
after administrating AST-120, which means
AST-120 is effective in delaying the progression
of CKD.
Fig. 2. (A), (B) pre- vs. post-treatment slope on reci-
procal of serum creatinine (1/sCr) and estimated
GFR (eGFR) in DM and non-DM patients. There
are no statistically significant differences between
DM and non-DM patients in blunting the slope of
1/sCr or eGFR, and both groups show delays in
the CKD progression.
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4. The difference in effects of AST-120 by age
The subgroups of patients aged over 70 and below
70 were comprised of 69 patients and 126 patients,
respectively. In subgroup of age over 70, the slope
of 1/sCr has blunted from -0.0078 0.0392 to±
-0.0030 0.0161 dL/mg/month (p<0.01), and that of±
eGFR has blunted from -1.0513 1.9740 to 0.2339± ±
1.2405 mL/min/1.73m2/month (p<0.01). On the other
hand, in subgroup of age below 70, the slope of 1/sCr
has blunted from -0.0148 0.0264 to -0.0004± ±
0.0197 dL/mg/month (p<0.01), and that of eGFR has
blunted from -1.1960 2.5662 to -0.0131 1.4035± ±
mL/min/1.73m
2
/month (p<0.01). Both subgroups showed
statistically significant alleviation of the slope of 1/sCr
and eGFR between before and after AST- 120 admi-
nistration. There were no statistically significant dif-
ferences between subgroups of aged over 70 vs. below
70 in the effect of AST-120 (Fig. 3A, B).
5. Adverse effects of AST-120
Out of 195 patients who were surveyed in this
study, 6 patients (3.1%) suffered from constipation, 2
patients (1.0%) showed serum creatinine elevation, 2
patients (1.0%) showed poor oral intake and 1 patient
(0.5%) suffered from nausea and vomiting. There
were no serious or life-threatening adverse effects
that need discontinuation of AST-120 (Table 4).
DISCUSSION
The population with CKD is expanding worldwide.
In USA, approximately 470,000 people were diag-
nosed with ESRD in 2004 and around 10,000 patients
start dialysis every year
18)
. In Korea, 96,008 patients




Managing CKD is becoming more and more impor-
tant because CKD not only leads to ESRD, but also
increases risk of cardiovascular events and deaths
20-
24)
. Furthermore, the financial benefit by delaying the
progression of CKD cannot be ignored
25, 26)
.
In CKD, renal functional deterioration leads to
accumulation of uremic toxin which induces renal
inflammation and fibrosis and further deteriorates
renal function in vicious cycle
22, 27)
. AST-120 is an
oral adsorbent to adsorb uremic byproduct in gastro-
Table 4. Adverse Effects of AST-120










Fig. 3. (A), (B) pre- vs. post-treatment slope on recip-
rocal of serum creatinine (1/sCr) and estimated
GFR (eGFR) in patients over age of 70 and under
age of 70. There are no statistically significant
differences in patients aged over 70 and below 70
in blunting the slope of 1/sCr or eGFR, and both
groups show delays in the CKD progression.
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intestinal tract in the effort to break out of this vicious
cycle and has been available on the market since
1991. The mechanism of AST-120 is still not fully
understood but there had been many studies on the
mechanism of AST-120 on prevention of CKD pro-
gression. It is now proven that AST-120 can adsorb
indole derived from tryptophan by gastrointestinal
bacteria
28)
. Since indole is a precursor of indoxyl sul-
fate, AST-120 may reduce serum indoxyl sulfate
level29). Indoxyl sulfate can cause tubular hypertrophy
following glomerular sclerosis by stimulating the syn-
thesis of transforming growth factor- (TGF- )ß ß 30).
Glomerular sclerosis and interstitial fibrosis are irre-
versible changes in CKD. Consequently, blocking
indoxyl sulfate synthesis by AST-120 may reduce
the progression to ESRD.
Studies on the effect of AST-120 to delay the pro-
gression of CKD were mostly done in Japan. There
are several studies showing that AST-120 can retard
the progression of CKD when added to conventional
treatments. Sanaka et al. showed that AST-120 has
protective effect over renal function in diabetic nephr-
opathy with good control of blood pressure and hema-
tocrit over 30%
31)
. In Korea, there have been few
studies that showed the effect of AST-120 on clinical
basis.
This study was focused on whether additional treat-
ment of oral AST-120 with conventional treatment
for CKD is effective in delaying progression to ESRD
in Korea. The result shows that administration of
AST-120 can delay the progression of CKD based on
the statistically significant blunting of the 1/sCr and
eGFR slope after AST-120 administration. The sub-
group analysis showed no significant difference in the
effect of AST-120 between both DM and non-DM
groups.
Ueda et al. showed that long term treatment with
AST-120 is effective in delaying the progression of
CKD, regardless of whether the patients had DM or
not32), which is consistent with this study.
Maeda et al. demonstrated that the patients aged
over 70 showed more blunting of reciprocal serum
creatinine slope than younger patients
5)
, but the re-
sult was not consistent with this study. Maeda et al.
suggested that the difference might be caused by that
older patients tends to comply to the prescription bet-
ter than younger patients or since elderly patients
tend to eat less, and it might be easier to maintain a
better life style, especially a low protein diet. How-
ever, in this study, the compliance of AST-120 and
low protein diet was strictly checked.
On the contrary to these positive reports, Akizawa
et al reported that AST-120 did not substantially slow
the progression of kidney disease in patients with
moderate to severe CKD during 1 year. But, as it was
mentioned in the report, primary end-point events
occurred infrequently, and life style modification was
not strictly educated as this report
33)
.
As shown in table 4, only 11 out of 195 patients
experienced adverse effects which were not serious.
The most common adverse effects of AST-120 were
gastrointestinal symptom, such as constipation, abdo-
minal discomfort, nausea/vomiting.
The limitation of this study is that it is retrospective
and in small scale, so there is no control group to
compare the effect of AST-120. To further evaluate
the effect of AST-120, prospective study should be
carried on in a larger scale. And more studies are
needed to be done to elucidate the association bet-
ween pathophysiology of CKD and effect of AST-120
on CKD.
In conclusion, treatment of CKD patients by AST-
120 along with conventional treatments appears to
be beneficial in retarding the deterioration of renal
function and delaying the initiation of renal replace-
ment therapy without serious adverse effects.
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